Suscribirse

Gold nanoparticles: A plausible tool to combat neurological bacterial infections in humans - 20/09/18

Doi : 10.1016/j.biopha.2018.07.130 
Syed Mohd Danish Rizvi a, , Talib Hussain a, Abo Bakr Fathy Ahmed b, Thamir M. Alshammari c, Afrasim Moin b, Mohammed Qumani Ahmed d, George E. Barreto e, f, Mohammad Ajmal Kamal g, h, i, Ghulam Md Ashraf i,
a Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia 
b Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia 
c Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia 
d Department of Pharmacology, College of Medicine,University of Hail, Hail, Saudi Arabia 
e Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C, Colombia 
f Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile 
g Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Sydney, Australia 
h Novel Global Community Educational Foundation, Australia 
i King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia 

Corresponding author at: Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia.Department of Pharmacology and ToxicologyCollege of PharmacyUniversity of HailHailSaudi Arabia⁎⁎Corresponding author at: King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.King Fahd Medical Research CenterKing Abdulaziz UniversityP. O. Box 80216Jeddah21589Saudi Arabia

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 12
Iconografías 2
Vídeos 0
Otros 0

Abstract

Management of bacterial infections of central nervous system is a major challenge for the scientists all over the world. Despite the development of various potential drugs, the issue of central nervous system infections persists in the society. The main constraint is the delivery of drugs across the blood brain barrier and only a few drugs after meeting the stringent criteria could cross the blood brain barrier. On the other hand, certain bacterial pathogens could easily enter the brain by using several factors and mechanisms by crossing the blood brain barriers. Interestingly, in the recent past, gold nanoparticles have shown immense potential to overcome the issues associated with the treatment of central nervous system infections, especially due to their inherent ability to cross the blood brain barrier. Initially, the present review summarized the recent updates on the pathogenesis and factors involved in neurological bacterial infections, including the mechanism used by bacterial pathogens to cross the blood brain barriers. Thereafter, the emphasis of the review was on providing current information on gold nanoparticles pertinent to their applicability for the treatment of neurological infections. After discussing the background of neurological bacterial infections, the characteristic features, antibacterial properties, mechanisms of antibacterial action and ability to cross the blood brain barrier of gold nanoparticles have been summarized. Some of the features of gold nanoparticles that make them an ideal candidate for brain delivery are biocompatibity, stability, ability to get synthesized in different sizes with facile methods, surface affinity towards various functional groups, spontaneous crossing of blood brain barrier without applying any external field and most importantly, easy non-invasive tracing by CT imaging. The current updates on the development of gold nanoparticles based therapeutic strategies for the prevention and treatment of central nervous system infections have been discussed in the present study. However, further investigation would be required to translate these preclinical outcomes into clinical applications. Nevertheless, we could safely state that the information gathered and discussed in the present review would benefit the scientists working in the field of neuro-nanotechnology.

El texto completo de este artículo está disponible en PDF.

Abbreviations : CT, NIH, CDC, CD54

Keywords : Nanotechnology, Gold nanoparticles, Neurological bacterial infections, Bacterial meningitis, Blood brain barrier, Drug delivery


Esquema


© 2018  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 107

P. 7-18 - novembre 2018 Regresar al número
Artículo precedente Artículo precedente
  • Editorial Board
| Artículo siguiente Artículo siguiente
  • Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs
  • Munazza Tamkeen Fatima, Zeyaul Islam, Ejaj Ahmad, George E. Barreto, Ghulam Md Ashraf

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.